Bristol Excedrin first quarter sales up 38% to $66 mil. on migraine indication.
This article was originally published in The Tan Sheet
Executive Summary
EXCEDRIN SALES JUMP 38% TO $66 MIL. ON EXCEDRIN MIGRAINE APPROVAL in January, but overall in the first quarter, consumer medicine sales dropped 4%, Bristol-Myers Squibb announced April 21. Consumer medicine sales worldwide would have increased by 1% excluding the effect of foreign currencies, BMS noted. International consumer medicine sales dropped 6% (2% excluding foreign exchange). The decline overseas reflects the "low level of influenza in Europe" compared to the prior year, the company said.